Eric Hedrick
Keine laufenden Positionen mehr
Vermögen: 1 Mio $ am 31.10.2023
Profil
Eric E.
Hedrick formerly worked at Genentech, Inc., as Medical Director in 2009, Pharmacyclics LLC, as Interim Chief Medical Officer in 2011, Epizyme, Inc., as Chief Medical Officer from 2012 to 2014, BeiGene Ltd., as Chief Medical Officer from 2015 to 2016, BeiGene Ltd., as Chief Medical Officer-Immuno-Oncology, and EQRx, Inc., as Chief Physician Executive from 2020 to 2023.
Dr. Hedrick received his undergraduate degree from Boston University and doctorate degree from the University of Maryland.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
EQRX, INC.
0,12% | 01.01.2023 | 627 000 ( 0,12% ) | 1 Mio $ | 31.10.2023 |
Ehemalige bekannte Positionen von Eric Hedrick
| Unternehmen | Position | Ende |
|---|---|---|
| EQRX, INC. | Corporate Officer/Principal | 09.11.2023 |
| BEIGENE, LTD. | Technik-/Wissenschafts-/F&E-Leiter | 24.08.2016 |
| EPIZYME, INC. | Technik-/Wissenschafts-/F&E-Leiter | 31.10.2014 |
| PHARMACYCLICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01.09.2009 |
Ausbildung von Eric Hedrick
| University of Maryland | Doctorate Degree |
| Boston University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BEIGENE, LTD. | Health Technology |
| EQRX, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
